Optimization of IV Ketamine for Treatment Resistant Depression
Completed
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD. Ketamine, a high-affinity N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, has been used as a standard intravenous (IV) anesthetic agent for many years in both pediatric and adult patients. Beyond its well-established role in anesthesia and pain management, there is emerging evidence that ketamine may... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
12/27/2013
Locations: Michael E. Dabakey VA Medical Center & Baylor College of Medicine, Houston, Texas
Conditions: Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)